Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization.

Rahme, Elham; Nedjar, Hacene; Afif, Waqqas

Rahme, Elham; Nedjar, Hacene; Afif, Waqqas.

Afiliação

Rahme E; Department of Medicine, Division of Clinical Epidemiology, McGill University, Montreal, Quebec, Canada.
Nedjar H; Centre for Outcomes Research and Evaluation, Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.
Afif W; Centre for Outcomes Research and Evaluation, Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.

J Can Assoc Gastroenterol ; 3(6): 257-265, 2020 Dec.

Article em En | MEDLINE | ID: mdl-33241178

Palavras-chave

Administrative data; Chron's disease; Direct medical cost; Health services utilization; Refractory; Ustekinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google